Paired facial treatment with 755nm picosecond laser with diffractive lens array and 1060nm laser lipolysis of the submentum: An open‐label prospective trial

2021 ◽  
Author(s):  
Jordan V. Wang ◽  
Mitalee P. Christman ◽  
Hao Feng ◽  
Hyemin Pomerantz ◽  
Margo Lederhandler ◽  
...  
Keyword(s):  
Prospective Trial ◽  
Picosecond Laser ◽  
Diffractive Lens ◽  
Open Label ◽  
Lens Array ◽  
Laser Lipolysis

A Prospective, Split‐Face, Randomized Study Comparing a 755‐nm Picosecond Laser With and Without Diffractive Lens Array in the Treatment of Melasma in Asians

2020 ◽  
Author(s):  
Woraphong Manuskiatti ◽  
Chadakan Yan ◽  
Ploypailin Tantrapornpong ◽  
Kathryn Anne G. Cembrano ◽  
Thanya Techapichetvanich ◽  
...  
Keyword(s):  
Randomized Study ◽  
Picosecond Laser ◽  
Diffractive Lens ◽  
Lens Array ◽  
Split Face

Pairing Facial Fillers With 755-nm Picosecond Laser With Diffractive Lens Array

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jordan V. Wang ◽  
Nkemjika Ugonabo ◽  
Robert Anolik ◽  
Roy G. Geronemus
Keyword(s):  
Picosecond Laser ◽  
Diffractive Lens ◽  
Lens Array

Single-Session Treatment With Botulinum Toxin and 755-nm Picosecond Laser With Diffractive Lens Array

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jordan V. Wang ◽  
Christian A. Albornoz ◽  
Robert Anolik ◽  
Roy G. Geronemus
Keyword(s):  
Botulinum Toxin ◽  
Picosecond Laser ◽  
Single Session ◽  
Diffractive Lens ◽  
Lens Array

Phase II study of SM-88 in Ewing's and other sarcomas.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e23505-e23505
Author(s):  
Victoria S. Chua ◽  
Sant P. Chawla ◽  
Kitty Zheng ◽  
Ted Kim ◽  
Giuseppe Del Priore ◽  
...  
Keyword(s):  
High Risk ◽  
Prospective Trial ◽  
Median Number ◽  
Cross Resistance ◽  
Duration Of Treatment ◽  
Open Label ◽  
Durable Response ◽  
Phase 2 Trial ◽  
Acid Analogue ◽  
Prior Systemic Therapy

e23505 Background: Sarcomas are rare heterogeneous malignancies. Once recurrent, cure is uncommon. SM-88 (racemetyrosine) is an amino acid analogue with no known cross resistance to typical sarcoma regimens. Based on previous anecdotal experience in Ewing’s (EWS) we initiated a Phase 2 trial (HopES) in EWS and other sarcomas (Ss) after >1 prior systemic therapy. We now report preliminary data after having met prespecified continuation criteria. Methods: Open label prospective trial in 2 separate cohorts (EWS and Ss) of oral SM-88 used with MPS conditioning agents (SM-88 920 mg, methoxsalen 10 mg, phenytoin 50 mg, sirolimus 0.5 mg) all daily until progression. Results: As of Feb 5 2021, 10 pts with incurable sarcomas were enrolled; 4 had high risk but stable EWS. Average age 43.9 yrs (13–77); 70% white; 20% female. Median number of prior regimens 4 (1–9); 70% received prior RT; 50% prior surgery. Median time from initial diagnosis 39.5 months with 50% T2 (40% unknown), 30% M1 (30% unknown). Prespecified futility stopping was exceeded (i.e., >1 of first 5 subjects/cohort) upon achieving clinical benefit in each. Stable disease was achieved in 75.0% (6/8 with available data). Time on treatment (TTx) exceeded last known TTx in 80% (95% CI 44.4–97.5). Median SM-88 TTx was 4.9 vs 2.9 mo for prior TTx (logrank HR 0.53; p=0.12). One EWS subject had unresectable disease that became resectable, was completely resected, and remained disease-free for ≥ 6 months. Prior to SM-88, longest TTx was 12 mo (on IT*) and shortest TTx 1 mo (on IEV*) vs SM-88 TTx of 11.9 mo. An angiosarcoma subject had a 21% reduction in the sum of all target lesions and exceeded all prior TTx (including 8 mo on Ap/N* with 12+ mo duration of treatment of SM-88). There were no serious drug-related AEs. ECOG performance remained stable for all. Conclusions: SM-88 has exceeded pre-specified futility in both cohorts (EWS maintenance and Ss salvage). HopES continues to enroll toward the planned total of 12 subjects to more precisely define its benefit in this ultra-orphan, extremely recalcitrant disease. This trial now confirms the previously reported clinical utility of oral SM-88 in EWS and other high-risk sarcomas. Based on durable response (>6mo), SD and prolonged TTx, SM-88 warrants additional investigation in this setting. Clinical trial information: NCT03778996. [Table: see text]

scholarly journals Clomiphene fails to revert hypogonadism in most male patients with conventionally treated nonfunctioning pituitary adenomas

2011 ◽  
Vol 55 (4) ◽  
pp. 266-271 ◽  
Author(s):  
Rogerio Silicani Ribeiro ◽  
Julio Abucham
Keyword(s):  
Pituitary Adenomas ◽  
Erectile Function ◽  
Prospective Trial ◽  
Open Label ◽  
Dopaminergic Therapy ◽  
Testosterone Levels ◽  
Nonfunctioning Pituitary Adenomas ◽  
Before And After ◽  
Previously Treated ◽  
Male Patients

OBJETIVE: To evaluate the effect of clomiphene in men with hypogonadism and conventionally treated nonfunctioning pituitary adenomas (NFPA). PATIENTS AND METHODS: Open label, single-arm, prospective trial. Nine hypogonadal men (testosterone < 300 ng/dL and low/normal LH) with previously treated NFPA. Clomiphene (50 mg/day orally) for 12 weeks. Testosterone, estradiol, LH, FSH, prolactin and erectile function were evaluated before and after 10 days, 4, 8 and 12 weeks of clomiphene treatment. RESULTS: After clomiphene treatment, testosterone and erectile function improved in only one patient. In the remaining eight patients, testosterone levels decreased whereas LH, FSH, and estradiol remained unchanged. Insulin sensitivity increased in unresponsive patients. CONCLUSIONS: Compared with hypogonadal men with prolactinomas under dopaminergic therapy, clomiphene treatment failed to restore normal testosterone levels in most patients with conventionally treated NFPA.

Sign in / Sign up

Export Citation Format

Share Document